图书简介
“Precision/personalized or stratified medicine” refers to the tailoring of medical treatment or drug administration to the individual characteristics of each patient treatment. It does not literally mean that a pharmaceutical company makes a drug for an individual patient for consumption and treatment but rather means the ability to stratify (or classify) individuals into sub-populations that differ in their responsiveness to a specific drug. A marker that provides information on the likely response to therapy, i.e., either in terms of tumor shrinkage or survival of the patient is termed “predictive biomarker”.Despite their promise in precision medicine and the explosion of knowledge in this area, there is not a single source on this subject that puts all this evidence together in a concise or richly illustrated and easy to understand manner. This book provides a collection of ingeniously organized, well-illustrated and up-to-date authoritative chapters divided into five sections that are clear and easy to understand. Section one provides an overview of biomarkers, introduces the basic terminologies, definitions, technologies, tools and concepts associated with this subject in the form of illustrations/graphics, photographs and concise texts. Several recent biomarker endeavors that have been initiated and funded by the National Cancer Institute, National Institutes of Health, FDA and other International organizations are presented.Section two involves the signaling pathways controlling cell growth and differentiation altered in cancer. This section analyzes how predictive biomarkers are altered (expressed or amplified) across cancer types.Section three explores how predictive biomarkers play a role in patient stratification and tailored treatment in relationship to specific cancers. In addition, it includes discussion on the various precision medicine initiatives that are going on across the globe (e.g. TARGET, NCI-MATCH, BATTLE, SHIVA, etc.).Section four discusses: (a) how pharmaceutical companies validate predictive biomarker assays and accompanying companion diagnostics either internally or externally with partner companies such as central laboratories or clinical research organizations, and (b) how predictive biomarker tests fall under the oversight of US FDA, Centers for Medicare & Medicaid Services (CMS) and state laws.Section five wraps up novel agents and targets that are being used as targets for cancer therapeutics. The biomarkers associated with these protocols will also be presented.Throughout the book, sidebars, special interest boxes and illustrations are used to explain terms that are either newly introduced, uncommon, or specialized. Predictive Biomarkers in Oncologywill serve as a definitive guide for practicing pathologists, oncologists, basic researchers, and personnel in the pharmaceutical or diagnostic industry interested in learning how “predictive biomarkers” are used in precision cancer therapy.
Introduction to Predictive Biomarkers: definitions and characteristics.- Introduction to clinical trials, clinical trial designs and statistical terminology used for predictive biomarker research and validation.- Overview of Methods Used in Predictive Biomarker Studies in a Molecular Anatomic Pathology Laboratory.- Significance of Immunohistochemistry and In Situ Hybridization Techniques for Predictive Biomarker Studies.- Overview of PCR-based Technologies and Multiplexed Gene Analysis for Biomarker Studies.- Introduction to Microarray Technology.- Digital and Computational Pathology for Biomarker Discovery.- Detection of Predictive Biomarkers Using Liquid Biopsies.- Measurement of Predictive Cancer Biomarkers by Flow Cytometry.- Personalized Cancer Treatment and Patient Stratification Using Massive Parallel Sequencing (MPS) and Other OMICs Data.- Bioinformatic Methods and Resources for Biomarker Discovery, Validation, Development, and Integration.- Overview of Cell Signaling Pathways in Cancer.- Steroid Hormone and Nuclear Receptor signaling pathways.- Protein kinase C Signaling in Carcinogenesis.- Roles of Rho/ROCK in Cancer Signaling.- Mitogen Activated Protein Kinase (MAPK) Signaling.- Notch Signaling Pathway in Carcinogenesis.- Signaling of the ErbB receptor Family in Carcinogenesis and the Development of Targeted Therapies.- Signaling Pathways in Tumor Angiogenesis and Anti-angiogenic Therapies in Human Cancer.- Role of PI3K/AKT/mTOR in Cancer Signaling.- Met Signaling in Carcinogenesis.- Role of Insulin-like Growth Factor Receptors in Cancer Signaling.- Role of Wnt/?-catenin Pathway in Cancer Signaling.- Hedgehog Signaling in Carcinogenesis.- TGF-? and the SMAD Signaling Pathway in Carcinogenesis.- Role of JAK-STAT Pathway in Cancer Signaling.- NF-kB signaling pathways in Carcinogenesis.- Immune-Signaling in Carcinogenesis.- Predictive Biomarkers and Targeted Therapies in Immuno-Oncology.- Role of Protein Tyrosine Phosphatases in Cancer Signaling.- Predictive and Prognostic Biomarkers in Myeloid Neoplasms.- Predictive Biomarkers and Targeted Therapies for Lymphoid Malignancies.- Targeted Therapies for Pediatric Central Nervous System Tumors.- Predictive Biomarkers and Targeted Therapies in Adult Brain Cancers.- Predictive Biomarkers and Targeted Therapies in Breast Cancer.- Predictive Biomarkers in Lung Cancer.- Predictive Biomarkers and Targeted Therapies in Genitourinary Cancers.- Predictive Biomarkers and Targeted Therapies in Colorectal Cancer.- Predictive Markers and Targeted Therapies in Gastroesophageal Cancer (GEC).- Predictive Biomarkers and Targeted Therapies in Hepatic, Pancreatic, and Biliary Cancers.- Gynecological Cancers & Head and Neck Cancers.- Predictive Biomarkers and Targeted Therapies in Head and Neck Cancer.- Predictive Biomarkers and Targeted Therapies in the Skin.- Predictive Biomarkers and Targeted Therapies in Sarcomas.- Predictive Markers and Targeted Therapies in Thyroid Cancer and Selected Endocrine Tumors.- The Response Evaluation Criteria in Solid Tumors (RECIST).- IVDs and FDA Marketing Authorizations: A General Overview of FDA Approval Process of an IVD Companion Diagnostic Device in Oncology.- Quality Control of Immunohistochemical and In Situ hybridization Predictive Biomarkers for Patient Treatment: Experience from International Guidelines and International Quality Control Schemes.- Use of Companion Diagnostics (CDx) and Predictive Biomarkers for Cancer Targeted Therapy. Clinical Applications in Precision Medicine.- Policy issues in the clinical development and use of predictive biomarkers for molecular targeted therapies.- Role of central laboratories in research, validation and application of predictive biomarkers.- Prominent Precision Medicine Clinical Trials in Oncology Around the World.- Precision Medicine Clinical Trials: Successes and Disappointments, Challenges and Opportunities. Lessons Learnt.- FDA Approved Targeted Therapies in Oncology.
Trade Policy 买家须知
- 关于产品:
- ● 正版保障:本网站隶属于中国国际图书贸易集团公司,确保所有图书都是100%正版。
- ● 环保纸张:进口图书大多使用的都是环保轻型张,颜色偏黄,重量比较轻。
- ● 毛边版:即书翻页的地方,故意做成了参差不齐的样子,一般为精装版,更具收藏价值。
关于退换货:
- 由于预订产品的特殊性,采购订单正式发订后,买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性,发生以下情况的,请直接拒收货物,由快递返回:
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全(例如:光盘等)
并请在工作日通过电话400-008-1110联系我们。
- 签收后,如发生以下情况,请在签收后的5个工作日内联系客服办理退换货:
- ● 缺页/错页/错印/脱线
关于发货时间:
- 一般情况下:
- ●【现货】 下单后48小时内由北京(库房)发出快递。
- ●【预订】【预售】下单后国外发货,到货时间预计5-8周左右,店铺默认中通快递,如需顺丰快递邮费到付。
- ● 需要开具发票的客户,发货时间可能在上述基础上再延后1-2个工作日(紧急发票需求,请联系010-68433105/3213);
- ● 如遇其他特殊原因,对发货时间有影响的,我们会第一时间在网站公告,敬请留意。
关于到货时间:
- 由于进口图书入境入库后,都是委托第三方快递发货,所以我们只能保证在规定时间内发出,但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间:
- 010-68433105/3213正常接听咨询电话的时间为:周一至周五上午8:30~下午5:00,周六、日及法定节假日休息,将无法接听来电,敬请谅解。
- 其它时间您也可以通过邮件联系我们:customer@readgo.cn,工作日会优先处理。
关于快递:
- ● 已付款订单:主要由中通、宅急送负责派送,订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐